Introduction {#Sec1}
============

Numerous reviews have been written about neuropathic pain (NP) in general (see, e.g., Baron [@CR26]; Campbell and Meyer [@CR60]; Colloca et al. [@CR78]; Meacham et al. [@CR268]) and painful diabetic neuropathy (pDN) in particular (see, e.g., Feldman et al. [@CR135]; Nawroth et al. [@CR289]; Sloan et al. [@CR358]). Many of them gave insight into recent findings on mechanisms of NP that may help to understand and further develop strategies for correct diagnosis and successful treatment. Although screening and diagnostic tools have become more and more available (Haanpaa et al. [@CR179]), NP is considered to be an underdiagnosed condition because a clear, comprehensive classification has been lacking until recently (Finnerup et al. [@CR141]). NP is no longer called "chronic intractable pain", but its management remains difficult: with current pharmacologic concepts that are internationally recommended by guidelines, only 30% of patients experience a pain reduction of about 30% (Finnerup et al. [@CR142]). The aim of this paper is to review mechanisms, assessment, classification, and management of peripheral NP. We will also discuss to what extent these underlying mechanisms have been considered in the development of diagnostic or treatment strategies in patients with painful (pDN) and painless diabetic polyneuropathy (dPNP) and what has proven to be useful. Given the importance as a global burden and rising number in patients as one of the main causes of NP (Rice et al. [@CR325]; IDF Diabetes Atlas; van Hecke et al. [@CR403]), the main focus will be on pDN due to its high and increasing prevalence.

Definitions {#Sec2}
-----------

According to the taxonomy of the International Association for the Study of Pain (IASP 2011; Loeser and Treede [@CR245]), neuropathic pain (NP) is defined as "*pain caused by a lesion or disease of the somatosensory nervous system*". The definite diagnosis of NP requires a demonstrable underlying lesion or disease satisfying established neurological diagnostic criteria (Finnerup et al. [@CR143]; Loeser and Treede [@CR245]; Treede et al. [@CR390]). Painful diabetic neuropathy (pDN) is a frequent subtype of peripheral NP; it is defined as "*pain as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes*" (Jensen et al. [@CR212]; Tesfaye et al. [@CR378]).

IASP taxonomy differentiates NP from nociceptive pain and---more recently---nociplastic pain. Nociceptive pain describes "*pain through activation of nociceptors in non-neural tissues by actual or threatened tissue injury*", while nociplastic pain is defined as "*pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain*" (IASP [@CR199]; Kosek et al. [@CR229]; Loeser and Treede [@CR245]). This distinction is essential, as different underlying mechanisms explain different treatment targets and responses to drugs. However, patients may present a substantial overlap of neuropathic and nociceptive pain in the same areas, e.g., in low back pain, postsurgical pain or osteoarthritis; this overlap has been called "mixed pain" (Freynhagen et al. [@CR151]). Patients with substantial overlap of neuropathic and nociplastic pain are likely to exist also, but there are no systematic studies yet.

Classification of neuropathic pain {#Sec3}
----------------------------------

Neuropathic pain may be classified according to the underlying lesion or disease (Scholz et al. [@CR342]) or according to the clinical phenotype (Vollert et al. [@CR412]). While the clinical phenotype may be useful for future personalized NP management (see below), the 11th edition of the International Classification of Diseases (ICD-11) differentiates NP of peripheral and central origin, comprising nine typical conditions associated with persistent or recurrent pain (Scholz et al. [@CR342], Table [1](#Tab1){ref-type="table"}). There are also extension codes for pain severity (combining intensity, distress, and disability), temporal characteristics and psychological or social factors, as well as a link to the International Classification of Functioning (ICF) (Scholz et al. [@CR342]; Treede et al. [@CR391]; Nugraha et al. [@CR294]; WHO Classification [@CR432]). Generally, NP is considered to be chronic, as it either persists continuously or manifests with recurrent painful episodes and is usually not limited by the natural healing process or treatment of the underlying disease. The IASP classification of chronic NP for ICD-11 represents the first systematic classification to date of common painful neurological disorders; member states are expected to report health statistics to WHO according to ICD-11 from 2022 onward. Thus, pDN is classified as *chronic NP* (top /first-level diagnosis) of peripheral origin (*chronic peripheral NP*; second-level diagnosis), *painful polyneuropathy* (third-level diagnosis) (Scholz et al. [@CR342]). From the clinical point of view, a physical examination is crucial to (1) link the patient's pain to a lesion or disease of the somatosensory nervous system, (2) to distinguish the NP component from nociceptive pain, and (3) to distinguish the NP component from nociplastic pain.Table 1Classification of chronic neuropathic pain in ICD-11*Top/first-level diagnosis*Chronic neuropathic pain*Second-level diagnosis*Chronic peripheral NPChronic central NP*Third-level diagnosis*Trigeminal neuralgia^a^Chronic NP after peripheral nerve injury^a^Painful polyneuropathyPostherpetic neuralgiaPainful radiculopathyChronic central NP associated with spinal cord injury^a^Chronic central NP associated with brain injury^a^Chronic central post-stroke painChronic central NP associated with MSAccording to Scholz et al. ([@CR342])^a^ICD-11 introduces the concept of multiple parenting, i.e., certain diagnoses may be listed in other divisions of the chronic pain classification, too, such as chronic posttraumatic pain or orofacial pain. Here, multiple parents are not listed for better readability

Etiology {#Sec4}
--------

Neuropathic pain may result from a broad range of diverse neurological disorders affecting the peripheral or the central nervous system (Table [2](#Tab2){ref-type="table"}). Chronic pain may also occur in neurological conditions of unknown etiology, i.e., idiopathic neuropathies (Colloca et al. [@CR78]). However, not all patients affected by neural disorders or lesions do develop NP. Extent and severity of NP vary markedly between patients suffering from the same underlying disease or neural lesions, particularly in diabetic polyneuropathy (dPNP) (Themistocleous et al. [@CR381]). Whether or not patients develop NP seems to be a multifactorial interaction of psychosocial, genetic, biological, and clinical risk factors (Hebert et al. [@CR187]). A large (\~ 10,000 participants), currently running multi-center observational study, DOLORisk, aims to elucidate these risk factors of development of NP (Pascal et al. [@CR302]).Table 2Neuropathic pain due to peripheral nerve damageEtiologyTypical syndromes (examples)Experimental modelsMechanical (compressive/traumatic)Carpal tunnel syndromePostsurgical painPainful radiculopathyCancer painPhantom limb painComplete or partial nerve transection, chronic constriction or compression of peripheral nervesMetabolic/ischemicDiabetic polyneuropathyVitamin B12 deficiencydPNP: hyperglycemic condition or streptozotocin induced; genetic modelsInflammatory (infectious/autoimmune)Post-herpetic neuralgiaHIV neuropathyLeprosyGuillain--Barré SyndromeCritical illness polyneuropathyInjection of viral proteins or cells systemically or specifically to e.g., sciatic nerveRat sepsis model^a^ToxicChemotherapy-induced peripheral neuropathyAlcoholic neuropathyInjection of drugs or ethanol, systemically or specifically to, e.g., sciatic nerveRadiationPost-radiation neuropathyX-radiation on peripheral nerves of the mouse^d^HereditaryCharcot--Marie--Tooth diseaseFabry diseaseGenetic model (e.g., α-GAL-deficient mice for Fabry disease)Typical neuropathic pain syndromes^b^ and corresponding experimental animal models^c^, sorted according to mechanisms of peripheral nerve damage (etiologies)*dPNP* diabetic polyneuropathy^a^Nardelli et al. ([@CR287])^b^For a very detailed overview of possible causes of NP, see review by Jay and Barkin ([@CR208])^c^For more details on animal models of NP in general, see Jaggi et al. ([@CR205]), Gregory et al. ([@CR173]), and Challa ([@CR65]). For animal models particularly on dPNP, see Gao and Zheng ([@CR155])^d^Love ([@CR246]) and Jiang et al. ([@CR216])

Epidemiology {#Sec5}
------------

Chronic NP frequently causes major suffering, a reduced quality of life and disability in patients, and is a major factor contributing to the global burden of disease (Doth et al. [@CR109]; Smith and Torrance [@CR359]; Alleman et al. [@CR9]; Rice et al. [@CR325]). For the general population, a prevalence of NP of 6.9--10% is estimated (Bouhassira et al. [@CR46]; Attal et al. [@CR20]). The prevalence of NP is likely to increase as we are facing, among other risk factors, an aging population, increasing obesity rates and an increase in survival of cancer patients that may suffer from sequelae of chemotherapeutics (Moulin et al. [@CR286]). However, systematic registration of incidence and prevalence of NP in the general population is difficult because the current versions of the International Classification of Disease (ICD-9 or ICD-10) are focused on the underlying lesions or diseases and not on whether or not they are painful (Finnerup et al. [@CR141]). Such data have only been obtained by dedicated surveys in certain countries or for certain etiologies (Colloca et al. [@CR78]). Generally, the association of pain and the underlying neurological disease is highly variable. While in some diseases such as postherpetic neuralgia or trigeminal neuralgia, pain is the most prominent manifestation, in others such as chemotherapy-induced neuropathy or dPNP, it may occur only in a subgroup of patients (Table [3](#Tab3){ref-type="table"}). Even among patients with the same underlying cause of NP, painful symptoms and signs may differ depending on the studied population, the diagnostic tools or criteria (Nawroth et al. [@CR289]).Table 3Prevalence of neuropathic pain in the general population and in common underlying diseasesGeneral population6.9 to 10%Bouhassira et al. ([@CR46]), Colloca et al. ([@CR78]), Attal et al. ([@CR20])*Central neuropathic pain*Spinal cord injury53 to 85%Burke et al. ([@CR54]), Hatch et al. ([@CR184])Stroke8 to 30%Delpont et al. ([@CR97])Multiple sclerosis29%Foley et al. ([@CR144])*Peripheral neuropathic pain*Herpes zoster5 to 67%Mallick-Searle et al. ([@CR256]), Forbes et al. ([@CR145])Postherpetic neuralgia^a^100% per definitionDiabetes mellitus \~ 20 to 50%Alleman et al. ([@CR9]), Sloan et al. ([@CR358])HIV neuropathy \~ 20%Ellis et al. ([@CR125])Trigeminal neuralgia^a^100% per definitionPost amputation60%Manchikanti and Singh ([@CR257])Post-surgical10--50%Borsook et al. ([@CR40])Most references are specific systematic literature reviews. Some did include questionnaire-based screening for the assessment of NP or telephone interviews for follow-up. Ellis et al. ([@CR125]) is about the CHARTER study, a longitudinal cohort study^a^These diseases are neuropathic pain conditions according to their clinical definition

Given the increasing prevalence of diabetes mellitus (DM) worldwide, dPNP is and will be one of the most important and common causes of NP. In 2000, 171 million (2.8% of the world population) people suffered from DM (Wild et al. [@CR424]), projections at the time for 2030 of 366 million (4.4%) are already by far surpassed. Today, in 2019, 425 million (8.6%) are affected; in 2045 629 million (9.8%) people are expected with DM worldwide (IDF Diabetes Atlas; United Nations ([@CR400]) Revision of World Population Prospects). dPNP is a frequent complication of long-term diabetes and one of the leading causes of morbidity and disability. While up to 60% in patients with chronic DM are affected by dPNP, already in newly diagnosed patients, 7--10% suffer from neuropathy (Tracy and Dyck [@CR388]; Tesfaye [@CR378]; Abbott [@CR2]). It seems to be generally more prevalent in Europeans as compared with Asians (Abbott et al. [@CR1]). In dPNP, NP is one of the main symptoms. Mostly, patients suffering from pDN are regarded as a subgroup of dPNP patients (≤ 60%, Abbott et al. [@CR2]). However, in one-fourth of all DM patients, painful symptoms occur without any other signs of neuropathy (Abbott et al. [@CR2]). Of all DM patients, 20--50% suffer from pDN (Abbott et al. [@CR2]; Bouhassira et al. [@CR47]; Alleman et al. [@CR9]; Sloan et al. [@CR358]; Truini et al. [@CR394]).

The burden of disease in pDN is much higher than in other chronic pain conditions (Sadosky et al. [@CR330]) resulting in reduced health-related quality of life (van Acker [@CR401]; Callaghan et al. [@CR56]; Smith et al. [@CR359]; Bouhassira et al. [@CR47]; Alleman et al. [@CR9]; Finnerup et al. [@CR142]; Finnerup et al. [@CR143]): comorbidities, such as sleep disorders, anxiety/depression (Gore et al. [@CR169]; Jain et al. [@CR206]) and cardiovascular diseases (Sadosky et al. [@CR330]), and "severe" pain in more than half of the affected patients (Sadosky et al. [@CR330]). Even 10-year mortality is higher in patients suffering from pDN than in patients without pain (Torrance et al. [@CR386]).

Pathophysiology of peripheral neuropathic pain {#Sec6}
==============================================

Neuropathic pain (NP) can be divided into central or peripheral syndromes, depending on the site of lesion or underlying disease. This section focuses on conditions that are considered consequences of a peripheral insult. Central NP conditions are less well understood and might differ in their underlying mechanisms, so they need separate consideration (Watson and Sandroni [@CR420]).

Peripheral nerve damage provokes persistent maladaptive structural and functional responses in the somatosensory system. Therefore, peripheral NP results from both, peripheral and central mechanisms. Clinical signs include sensory loss, spontaneous (ongoing) pain and hypersensitivity, including allodynia and hyperalgesia (evoked pain) (Jensen and Finnerup [@CR209]).

Most of the current ideas regarding the pathophysiology of NP have been derived from animal models of mechanical nerve damage, such as spared nerve injury (SNI), chronic constriction injury (CCI), and spinal nerve ligation (SNL). Additionally, pathogenesis of NP has also been studied in rodent models of diabetes, chemotherapy, herpes zoster and HIV--peripheral neuropathy (Colleoni and Sacerdote [@CR77]). These preclinical studies delineated a series of mechanisms along the entire nervous system (Fig. [1](#Fig1){ref-type="fig"}). In the peripheral nervous system (PNS), nerve damage leads to reduced signal transmission to the spinal cord and alterations in gene expression patterns and ion channel properties leading to ectopic activity. In the central nervous system (CNS), enhanced synaptic transmission and disinhibition at the spinal, thalamic and cortical level lead to amplified central processing. Human studies revealed some of these mechanisms in patients with NP and in human surrogate models of NP (Binder [@CR37]; Klein et al. [@CR226]; Vollert et al. [@CR412]). In the following sections, a short overview of these mechanisms is given to understand current and future strategies for the assessment and treatment of NP.Fig. 1Selection of peripheral and central mechanisms contributing to neuropathic pain. *AMPA-R/NMDA-R* ionotropic glutamate receptors, *AP* action potential, *ATP* adenosine triphosphate, *BDNF* brain-derived neurotrophic factor, *CCL2/FKN* chemokines, *CCR2/CX3CR1* chemokine receptors, *CGRP* calcitonin gene-related peptide, *GABA* gamma-aminobutyric acid, *Gly* Glycin, *FKN* fractalkine (CX3CL1), *IL-1β* interleukin 1β, *IL-6* interleukin 6, *KCC2* chloride potassium symporter, *MMP* matrix metalloproteinase, *NK1-R* neurokinin 1 receptor, *NO* nitric oxide, *p-p38* MAPK phosphorylated p38 mitogen-activated protein kinase, *PG* prostaglandins, *SP* substance P, *TNFα* tumor necrosis factor-alpha, *TNF-R* tumor necrosis factor receptor, *trkB* tyrosine kinase B, *TRPV1* transient receptor potential vanilloid 1, *VGSC* voltage-gated sodium channel

Mechanisms of sensory loss {#Sec7}
--------------------------

After peripheral nerve injury, neurodegeneration disrupts the connection between the periphery and the CNS, ultimately resulting in sensory loss. After transection of axons of primary sensory neurons, the distal axons die due to Wallerian degeneration (Campbell and Meyer [@CR60]), particularly affecting small-fiber neurons including nociceptors (Tandrup et al. [@CR373]). Later on, persistent aberrant afferent input may provoke the degeneration of superficial dorsal horn neurons via glutamate-mediated excitotoxicity (Scholz et al. [@CR340]). Neuroimaging studies in patients with NP hint that neurodegeneration may also occur in the brain (May [@CR265]).

Mechanisms of ongoing pain {#Sec8}
--------------------------

Meanwhile, the proximal remnants of the fibers (e.g., C-fibers) at the injury site can generate ectopic activity and so pain originates from an area with reduced sensitivity to thermal and mechanical stimuli. Microneurographic recordings of single C-fibers have demonstrated spontaneous activity in human studies investigating several NP syndromes (Serra et al. [@CR350]). Ongoing pain, such as burning ongoing pain and spontaneous shock-like pain, is the most prevalent feature and most troublesome clinical sign in NP syndromes (Gold and Gebhart [@CR165]). Since ongoing pain can be temporarily abolished by blocking peripheral input, research focuses on the primary afferent fiber as the origin of ongoing pain (Gracely et al. [@CR170]; Haroutounian et al. [@CR183]). Ongoing pain is thought to result from ectopic action potential (AP) generation within the nociceptive pathways through enhanced synaptic transmission to the spinal neurons and/or enhanced intrinsic excitability of second-order neurons (Woolf et al. [@CR430]; Balasubramanyan et al. [@CR24]; Hains and Waxman [@CR180]). Ectopic discharge was originally described as arising only at the site of the nerve lesion (Wall and Gutnick [@CR414]), but can occur at multiple sites, including the site of injury, along the axon and in the dorsal root ganglia (DRG) of nociceptors (Devor [@CR104]). Enhanced sensitivity of primary sensory neurons to endogenous thermal and chemical stimuli may also cause spontaneous pain.

Ectopic discharge is associated with increased expression of voltage-gated sodium channels (VGSC) in primary afferents (Cummins et al. [@CR92]). Clustering of VGSC might lower the action potential (AP) threshold at sites of ectopic impulses resulting in hyperexcitability (Lai et al. [@CR235]). In peripheral sensory neurons, the VGSC subtypes Nav1.7, Nav1.8, and Nav1.9 are particularly prevalent. Their contribution to pain pathogenesis varies in different NP conditions (Dib-Hajj et al. [@CR107]; Hameed [@CR181]). Rare inherited channelopathies show a crucial role of VGSC in pain processing (Bennett and Woods [@CR34]; Hoeijmakers et al. [@CR192]); loss-of-function mutations in Nav1.7 are associated with insensitivity to pain (Cox et al. [@CR85]), while gain-of-function mutations in Nav1.7 lead to hyperexcitability and pain disorders in humans, erythromelalgia and paroxysmal extreme pain disorder (Estacion et al. [@CR128]). Neurotrophic factors induce alterations in the VGSC, e.g., time-dependent changes in Nav1.8 (Amir et al. [@CR12]; Coward et al. [@CR84]), including upregulation, low excitability threshold and an increased suprathreshold ion current (Lai et al. [@CR236]). Nav1.9 might also contribute to increased excitability in NP (Hoffmann et al. [@CR193]). After nerve injury, large numbers of fast Nav1.3 are expressed, which otherwise are only present during embryonic development. Nav1.3 causes strong fluctuations of the membrane potential and is probably the cause of spontaneously arising AP bursts (Wood et al. [@CR426]).

Some NP conditions, however, are independent of VGSC (Minett et al. [@CR280]). Apart from VGSC, some types of calcium channels (Zamponi et al. [@CR440]), potassium channels (Busserolles et al. [@CR55]), and hyperpolarization-activated cyclic nucleotide-gated channels (Chaplan et al. [@CR68]) also contribute to hyperexcitability.

Peripheral nociceptor sensitization {#Sec9}
-----------------------------------

An important characteristic of nociceptors, such as unmyelinated (C) and thinly myelinated (Aδ) primary afferent neurons, is sensitization. Sensitization, which typically develops as a consequence of tissue injury and inflammation, is defined as a reduction in the threshold, an increase in the magnitude of response to noxious stimulation and spontaneous activity. The inflammatory processes in Wallerian degeneration may hence render the remaining intact fibers after nerve injury hyperexcitable (Campbell and Meyer [@CR60]).

The discovery of the transient receptor potential (TRP) family led to a better understanding of how nociceptors detect external stimuli and how they can be sensitized (Caterina et al. [@CR64]). TRP channels are activated by various nociceptive physical and chemical stimuli, providing the generator potential to activate VGSC resulting in ectopic discharge (reviewed in Mickle et al. [@CR276]). Proinflammatory mediators enhance TRPV1 channel function via phosphorylation, provoking peripheral sensitization. Sensitized TRPV1 gets activated by minimally acidic pH and at body temperatures, leading to sustained generator potentials and electrical discharge. Expression of TRPV1 can also be upregulated by nerve damage and the increased inflammatory microenvironment (reviewed in Mickle et al. [@CR276], [@CR277]). Translocation of TRPV1 to the cell surface also increases the channel activity. Activation of TRPV1 results in membrane depolarization with subsequent AP generation via VGSCs; TTX-insensitive sodium channels can also be sensitized via phosphorylation by protein kinases A and C (Gold et al. [@CR166]).

Neural damage provokes highly organized neuroimmune interactions in peripheral nerves that play a key role in initiating many cellular mechanisms underlying persistent NP (reviewed in Costigan et al. [@CR82]; Marchand et al. [@CR258]; Scholz and Woolf [@CR339]). Accumulation of infiltrating immune cells such as neutrophils, macrophages, and mast cells at the injured site contributes to peripheral sensitization in most neuropathic conditions (Ren and Dubner [@CR324]). They release substances (e.g., NO, ATP, lipids prostaglandins, cytokines, etc.), which sensitize the remaining intact axons and contribute to axonal damage. Schwann cells secrete nerve growth factor (NGF) and matrix metalloproteinases (MMPs) that contribute indirectly to central sensitization (see below). Neuropeptides from nociceptive axons, kinins, and nitric oxide cause a local increase in blood flow and tissue swelling. This neurogenic neuroinflammation affects the micromilieu in the nerve. After the damaged nerves are removed by phagocytosis, neuropathic sensitivity is then maintained by intact axons. Remarkably, similar changes also occur in the dorsal root ganglion (DRG).

Spinal sensitization {#Sec10}
--------------------

The IASP defines central sensitization as an "*increased responsiveness of nociceptive neurons in the CNS to their normal or subthreshold afferent input*" (Loeser and Treede [@CR245]). The main reason for central sensitization in peripheral NP is the persistent nociceptive afferent input after peripheral nerve damage (Haroutounian et al. [@CR183]). Blocking the afferent input, even in patients with profound signs of central sensitization, temporarily abolishes NP symptoms (Gracely et al. [@CR170]). Patients with NP show different signs of central sensitization, including a pattern of hyperalgesia similar to secondary hyperalgesia (i.e., an increase in pain sensitivity outside the area of injury).

Alterations in calcium permeability, gene expression patterns, phosphorylation of ion channels, neuronal plasticity, and the misbalance between descending facilitation and inhibition promote central sensitization (Latremoliere and Woolf [@CR238]). In animal models of peripheral nerve injury, activation of several protein kinases leads to phosphorylation of ionotropic and metabotropic glutamate receptors and subsequently to enhanced excitatory postsynaptic potential frequency and amplitude (Choi et al. [@CR74]; Hildebrand et al. [@CR190]). Ion channel alterations, such as upregulation of the α2δ-1 subunit of voltage-gated calcium channels (Luo et al. [@CR250]), occur after peripheral nerve damage.

Long-term potentiation (LTP), an activity-dependent persistent synaptic strengthening, intensively studied in the hippocampus, appears to play a role in spinal sensitization after noxious input (Ji et al. [@CR213]; Sandkuhler [@CR336]). There is still no proof of LTP in NP patients, but there are several lines of evidence in favor: conditioning electrical stimulation of the same type that induces LTP in rodents has been shown to induce long-lasting amplification of pain perception in humans (Klein et al. [@CR225]). Brief application of high-dose opioids reversed activity-dependent LTP at C-fiber synapses in preclinical studies (Drdla-Schutting et al. [@CR110]). Further studies need to investigate whether inhibition of LTP can also outlast drug effects in NP patients, which would suggest reversal of LTP and hyperalgesia.

Increased *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) activity contributes to central sensitization after nerve damage. Activation of intracellular pathways by protein kinases leads to phosphorylation of NMDARs. Afterwards, NMDARs respond stronger to agonists. Under normal circumstances, NMDA receptor channels are blocked by Mg^2+^ ions. Phosphorylation by protein kinase C increases the opening probability and decreases the affinity of NMDARs for extracellular Mg^2+^ (Chen and Huang [@CR70]). Activation of protein kinase C also facilitates the upregulation of NMDAR activity and enhances LTP (Lu et al. [@CR248]).

Activation of NMDARs boosts synaptic efficacy and causes Ca^2+^ influx, which can activate intracellular signaling pathways that initiate and maintain central sensitization. Targeting α2δ-1-bound NMDARs with gabapentinoids or α2δ-1 C-terminal peptides can attenuate nociceptive drive from primary sensory nerves to dorsal horn neurons in NP (Chen et al. [@CR71]).

Involvement of microglia in spinal sensitization {#Sec11}
------------------------------------------------

In the last decade, a growing body of literature has delineated neuronal interactions with non-neuronal cells and both their contributions to NP, particularly focusing on neurogenic neuroinflammation (i.e., inflammatory reactions in response to neuronal activity) (Xanthos and Sandkühler [@CR434]). While most studies on diseases of the CNS focus on how microglial-driven neurodegeneration develops, pain researchers turned to investigate mediators released by microglia that modulate synaptic transmission (Salter and Stevens [@CR334]; Woolf and Salter [@CR429]). Since the first role on the specific role of microglia in NP (Jin et al. [@CR217]; Raghavendra et al. [@CR318]; Tsuda et al. [@CR396]), evidence has grown on the role of microglia in preclinical models of NP (Clark and Malcangio [@CR75]; Inoue and Tsuda [@CR202]; McMahon and Malcangio [@CR267]; Tsuda et al. [@CR397]), the contribution of astrocytes is less clear. Since there is now great interest in targeting neuroinflammation to treat NP conditions, some of the neuronal microglial signaling pathways will be presented.

Microglia, the macrophages of the CNS, are found massively in the dorsal horn close to central terminals of damaged afferents (Beggs and Salter [@CR32]) soon after peripheral nerve injury. This activation is caused by several mediators acting on microglial receptors, e.g., ATP acting on P2X4 and P2X7 (Bernier et al. [@CR35]; Inoue [@CR201]; Tsuda et al. [@CR396]) or the two chemokines fractalkine (CX3CL1) and CCL2 acting on their specific receptors (CX3CR1, CCR2) (Clark and Malcangio [@CR76]; Milligan et al. [@CR279]; Thacker et al. [@CR380]; Zhuang et al. [@CR445]). Toll-like receptors are also involved in microglial activation (reviewed in Lacagnina et al. [@CR233]). Subsequently, microglial phenotype changes from a surveillance state to an activated state and several intracellular signaling cascades are activated, e.g., phosphorylation of p38 mitogen-activated protein kinase (MAPK) (Jin et al. [@CR217]). As a consequence, microglia release proinflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) (Schafers et al. [@CR338]), interleukin 1β (IL-1β) (Gruber-Schoffnegger et al. [@CR178]), and brain-derived neurotrophic factor (BDNF) (Coull et al. [@CR83]) that establish a positive feedback loop during nociceptive signaling and modulate spinal neurons leading to enhanced synaptic transmission (reviewed in Ji et al. [@CR214]; Tsuda et al. [@CR397]). Blocking microglial activation can prevent chronic pain, but cannot reverse it (Raghavendra et al. [@CR318]; Zhang et al. [@CR443]).

In humans, direct evidence of glial activation and its contribution to pain pathogenesis is scarce, but there is evidence of increased levels of proinflammatory mediators in cerebrospinal fluid (e.g., chemokines, TNF-alpha, IL-6) as well as low levels of the anti-inflammatory mediator IL-10 supporting the idea of central neuroinflammation in NP patients (Backonja et al. [@CR21]; Backryd et al. [@CR23]; Kotani et al. [@CR230]; Sun et al. [@CR370]). Elevated levels of a neuroinflammation marker translocator protein (TSPO) with in vivo PET/MR imaging in patients with several chronic pain states including lumbar radiculopathy were demonstrated (Albrecht et al. [@CR6]).

Supraspinal changes {#Sec12}
-------------------

Hyperexcitability of neurons in nociceptive pathways (Patel and Dickenson [@CR303]) and ion channel alterations (Shen et al. [@CR351]; Wang et al. [@CR418]) can also be found in higher brain regions in NP. Ectopic discharge in the CNS following neuronal disinhibition has been suggested (Keller et al. [@CR220]) and thalamic bursting discharge of patients with central NP may represent such ectopic activity (Lenz et al. [@CR241]). Microglial activation occurs in the thalamus, sensory cortex, and amygdala of the nociceptive pathways after peripheral nerve damage (Taylor et al. [@CR374]). This glial activation leads to enhanced synaptic plasticity in the primary somatosensory cortex, resulting in mechanical hypersensitivity (Kim et al. [@CR223]). Cellular events occurring during glial activation in the periaqueductal gray may also promote descending facilitation during NP (Ni et al. [@CR291]).

Descending pathways from the anterior cingulate gyrus, amygdala, and hypothalamus modulate the spinal transmission via brain stem nuclei in the periaqueductal gray and rostroventral medulla involving neurotransmitters such as norepinephrine, serotonin, and endogenous opioids. Under physiological conditions, there is a balance between descending facilitation and inhibition with a predominance of inhibition. Descending inhibition is at least partly mediated by spinal interneurons that act pre- or postsynaptically at the synaptic transmission from primary afferents to dorsal horn neurons (Zeilhofer et al. [@CR441]). Under pathological conditions, several mechanisms lead to reorganization in these pathways, including an altered transmembrane anion gradient (Keller et al. [@CR220]), microglial-driven downregulation of potassium chloride cotransporters (Coull et al. [@CR83]), loss of GABAergic interneurons (Moore et al. [@CR283]; Scholz et al. [@CR340]), impaired noradrenergic inhibition (Rahman et al. [@CR320]) and increased descending serotoninergic facilitation (Bee and Dickenson [@CR31]).

In human studies, conditioned pain modulation (CPM) gives insight into endogenous descending inhibition and facilitation (Gasparotti et al. [@CR156]; Kennedy et al. [@CR221]; Granovsky [@CR171]). In healthy volunteers, inhibitory effects dominate. Studies comparing healthy volunteers with patients with peripheral polyneuropathy have demonstrated significantly impaired CPM in nondiabetic painful neuropathy (Tuveson et al. [@CR398]) and in pDN patients (Granovsky et al. [@CR172]). CPM can predict the success of pain therapy (Bosma et al. [@CR41]; Yarnitsky et al. [@CR438]) and increasing CPM efficacy can also alleviate pain (Schuh-Hofer et al. [@CR345]).

Neuroimaging studies have shown multiple changes in activity and functional connectivity in CNS regions involved in pain processing and pain modulation (Moisset and Bouhassira [@CR282]). To date, there is no agreement on whether central sensitization acts only as an amplifier of peripheral signals (Meacham et al. [@CR268]) or as an independent pain generator in peripheral NP conditions (Ji et al. [@CR215]). Nevertheless, central mechanisms are essential for the maintenance and chronification of NP (Latremoliere and Woolf [@CR238]).

Assessment of peripheral neuropathic pain {#Sec13}
=========================================

Neuropathic pain (NP) describes a group of syndromes with many different causes and varying clinical manifestations. Diagnostic algorithms differ depending on whether the underlying lesion or disease is in the peripheral or central nervous system. Hence, a first subdivision of NP is peripheral versus central NP (Scholz et al. [@CR342]). The basic diagnostic approach (i.e., according to the grading system) is the same (Treede et al. [@CR390]; Finnerup et al. [@CR143]), but assessment tools are different (e.g., punch skin biopsy for peripheral vs. MR imaging for central NP).

Grading system for neuropathic pain assessment {#Sec14}
----------------------------------------------

The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) issued diagnostic criteria for NP, the Neuropathic Pain Grading System, developed to determine the level of certainty that a patient's pain is neuropathic in nature or has a neuropathic component in mixed pain syndromes (Finnerup et al. [@CR143]; Treede et al. [@CR390]); it was intended to be used for clinical diagnostics as well as clinical research. This diagnostic approach was also included in the assessment guidelines for NP (Cruccu and Truini [@CR88]; Deng et al. [@CR99]) and in ICD-11 (Scholz et al. [@CR342]). The stepwise approach is based on the history of the patient, physical examination, and confirmatory tests (Table [4](#Tab4){ref-type="table"}). The initial grading system (Treede et al. [@CR390]) struggled with the paradox that classical trigeminal neuralgia is not associated with sensory deficits in the painful area, yet is one of the commonly accepted peripheral NP syndromes. When evoked paroxysms of trigeminal neuralgia had been re-conceptualized as sensory signs (Cruccu et al. [@CR91]), the following hierarchical sequence of four steps could be established in the revised grading system (Finnerup et al. [@CR143]):Table 4A stepwise approach facilitates the classification of patients' pain as neuropathicDiagnostic stepOutcomeConclusion*History*(1) History of relevant neurological lesion or disease(2) And pain distribution, which is neuroanatomically plausibleBoth criteria "yes"'Possible neuropathic pain'*Examination*(3) Pain is associated with sensory signs in the same neuroanatomical plausible distributionPositive results in BSE or QST^a^'Probable neuropathic pain'*Confirmatory tests*(4) Diagnostic test confirming a lesion or disease of the somatosensory nervous system explaining the pain^b^Confirmed'Definite neuropathic pain'Stepwise approach for diagnosis of NP according to the Neuropathic Pain Grading System (Treede et al. [@CR390]; Finnerup et al. [@CR143])The levels "probable" and "definite" are both considered to establish the diagnosis, whereas the level "possible" is not^a^Usually signs of sensory loss, but also allodynia (touch evoked or thermal). *BSE* bedside examination, *QST* quantitative sensory testing^b^Different for peripheral neuropathic pain (blood glucose levels, HbA1c, nerve conduction studies, surgical evidence, etc.) or central neuropathic pain (MRI, CSF analysis, etc.)

Step 1: The medical history of the patient needs to suggest a lesion or disease that is capable of causing NP. Step 2: Pain distribution is plausible for the underlying lesion or disease (according to, e.g., pain drawing of the patient). When these two conditions are met, the possibility of NP is considered possible (*possible NP*). A detailed clinical examination should then be performed to find confirmatory evidence for the pain distribution and the underlying lesion or disease. Step 3: Since there is no confirmatory test for the spatial extent of perceived ongoing pain, the spatial extent of sensory signs is used as a surrogate. If this condition is also met, the neuropathic nature of the pain is considered to be likely (*probable NP*). Step 4: Depending on the suspected lesion or disease, appropriate confirmatory tests are performed. When positive, they lead to the diagnosis of "*definite NP*". The level "*probable NP*" is considered sufficient to initiate treatment. The level "*definite NP*" indicates that a physician is able to confirm that the patient has a neurological lesion or disease that might explain his/her pain (Finnerup et al. [@CR143]).

The steps in the grading system follow the usual algorithm of neurological diagnostics and are primarily based on clinical examination. Thus, the experience and skills of the physician who does the assessment are of importance and may be limiting. Most available guidelines agree with this, but applicability and usefulness for the day-to-day clinical setting are limited by test--retest reliability of clinical assessment (Cruccu and Truini [@CR88]; Deng et al. [@CR99]). It should be noted that even the level 'definite neuropathic pain' does not mean that causality has been established; it refers to the fact that a physician is able to confirm that the patient has a neurological lesion or disease that might explain his/her pain (Finnerup et al. [@CR143]). Lack of confirmation may, however, lead to underdiagnosing NP in patients with pain as their main or only symptom (Bouhassira and Attal [@CR43]; Cruccu et al. [@CR91]; Finnerup et al. [@CR143]; Scholz et al. [@CR342]). The level "probable NP" is hence considered sufficient to initiate treatment.

Screening as a first step towards diagnosis {#Sec15}
-------------------------------------------

Screening tools for NP are patient-reported questionnaires mostly based on pain descriptors or combined questionnaires and simple clinical tests (Table [5](#Tab5){ref-type="table"}, see also Colloca et al. [@CR78]; Attal et al. [@CR20]). They are widely used in daily clinical practice, especially by non-specialists to initiate necessary further diagnostic assessment (Haanpaa et al. [@CR179]). They are also popular in clinical research due to their simplicity and low cost. Screening tools had different objectives when being developed, and validity is inconsistent, as different reference standards were used (old vs. current definition of NP). The value of a screening tool also depends on reliability, sensitivity for changes, usability in another language after thorough translation, and cross-cultural adaptation process.Table 5Tools for identification and evaluation of symptoms of neuropathic pain and (painful) diabetic neuropathyAbbreviationFull nameObjective(s)DescriptionReferences*Neuropathic pain*DN4Douleur Neuropathique en 4 QuestionsTo compare the clinical features of *neuropathic and non-neuropathic painClinician-administered* questionnaire (10 items):7 sensory descriptors and 3 clinical signs related to bedside sensory examination, to be tested by the physicianBouhassira et al. ([@CR45])Spallone et al. ([@CR363])DN4-interviewDouleur Neuropathique en 4 Questions-InterviewTo compare the clinical features of *neuropathic and non-neuropathic painClinician-administered* questionnaire (7 sensory descriptors)Bouhassira et al. ([@CR45])Spallone et al. ([@CR363])NPSINeuropathic Pain Symptom InventoryTo evaluate the *different dimensions of symptoms of neuropathic painPatient self-administered* questionnaire (12 items):items related to different pain descriptors (e.g., burning, electric-shock like, squeezing, tingling)Bouhassira et al. ([@CR44])Crawford et al. ([@CR86])Lucchetta et al. ([@CR251])PainDETECTPainDETECTScreening for the presence of *neuropathic pain* without physical examination*Patient self-administered* questionnaire (10 items):1 item time course, 1 item pain intensity, 1 item pain radiation, 7 items pain descriptors (quality)Freynhagen et al. ([@CR150])Themistocleous et al. ([@CR381])*Painful diabetic neuropathy*DN4Douleur Neuropathique en 4 QuestionsTo compare the clinical features of *neuropathic and non-neuropathic painClinician-administered* questionnaire (10 items):7 sensory descriptors and 3 clinical signs related to bedside sensory examination, to be tested by the physicianBouhassira et al. ([@CR45])Spallone et al. ([@CR363])DN4-interviewDouleur Neuropathique en 4 Questions-InterviewTo compare the clinical features of *neuropathic and non-neuropathic painClinician-administered* questionnaire (7 sensory descriptors)Bouhassira et al. ([@CR45])Spallone et al. ([@CR363])mBPI-DPNModified Brief Pain InventoryModified version of the Brief pain Inventory for patients with *painful diabetic neuropathyPatient-completed* numeric rating scale to assess the severity of pain, the impact on daily functioning and other aspects of pain. A modification was made to distinguish between pain attributable to diabetic polyneuropathy and attributable to other causes.Zelman et al. ([@CR442])NSC-scoreNeuropathy Symptom and Change ScoreTo detect and grade the severity of *diabetic neuropathy* and *painClinician-administered* questions about the type of pain or slight illness, location of symptoms, time of symptom, arousal from sleep and maneuvers that are relieving patients' symptomsXiong et al. ([@CR435])NTSS-6Total Symptom Score 6To evaluate the frequency and intensity of *neuropathic sensory and pain symptoms* in patients with *diabetic peripheral neuropathyClinician-administered* 6-item questionnaire:frequency and intensity of: numbness and/or hyposensitivity; prickling and/or tingling; burning; aching pain and/or tightness; sharp, shooting, lancinating pain; and allodynia and/or hyperalgesia)Bastyr et al. ([@CR30])PainDETECTPainDETECTScreening for the presence of *neuropathic pain* without physical examination*Patient self-administered* questionnaire (10 items):1 item time course, 1 item pain intensity, 1 item pain radiation, 7 items pain descriptors (quality)Freynhagen et al. ([@CR150])Themistocleous et al. ([@CR381])*Diabetic neuropathy*CSSClinical screening scoreTo screen T2DM patients for *sensorimotorpolyneuropathy* and need for in-depth foot examination*Clinician-administered* evaluation of risk factors, diastolic blood pressure, creatinine serum levels, foot inspection and interview for pain and neuropathic symptomsBongaerts et al. (2015)DNEDiabetic Neuropathy Examination ScoreTo diagnose *distal diabetic polyneuropathyClinician-administered* (8 item) examination about muscle strength, reflexes and sensations (pinprick, SWMF, vibration and proprioception)Meijer et al. ([@CR270])Meijer et al. ([@CR272])Liyanage et al. ([@CR244])DNSDiabetic Neuropathy Symptom ScoreTo assess *distal neuropathy* in patients with *diabetesClinician-administered* (4 item) symptom score:1. Unsteadiness in walking, 2. Pain, burning or aching at legs or feet, 3. Prickling sensations in legs or feet and 4. Numbness in legs or feetMeijer et al. ([@CR271])Liyanage et al. ([@CR244])mTCNSModified Toronto Clinical Neuropathy ScoreTo modify the TCSS to better capture a categorical scale of simple sensory tests which are representative of the early dysfunction in *diabetic sensorimotorpolyneuropathyClinician-administered* symptom scores and sensory test scoresBril et al. ([@CR51])MNSIMichigan Neuropathy Screening InstrumentTo screen large numbers of patients in a routine clinical setting for the presence of *diabetic neuropathy*Patients who screen positive on the MNSI may be referred for the administration of the MDNSSection A: *self‐administered by the patient* through 15 "yes" or "no" questions about foot sensation, numbness, temperature alterations, general asthenia, and peripheral vascular diseaseSection B: based on clinical examination (*clinician*-*administered*): (1) inspection of both feet (2) examination and grading of muscle stretch reflexes (3) determination of vibration sensationFeldman et al. ([@CR133])Rahman et al. ([@CR319])Moghtaderi et al. ([@CR281])Xiong et al. ([@CR435])Barbosa et al. ([@CR25])Sartor et al. ([@CR337])MDNSMichigan Diabetic Neuropathy ScoreTo provide a means of diagnosing and staging *diabetic neuropathy* that is simpler and less time consuming than accepted research protocols*Clinician-administered* sensory impairment testing, muscle strength testing and reflexesFeldman et al. ([@CR133])NDSNeuropathy Disability ScoreTo detect *deficits affecting the peripheral nervous systemClinician-administered* evaluation of cranial nerves, muscle weakness, reflexes and loss of sensationsDyck et al. ([@CR117])Norfolk QoL-DNNorfolk Quality of life questionnaire -- diabetic neuropathyTo capture the entire spectrum of *diabetic neuropathy* including sensory loss of function, balance, motor impairments and autonomic symptoms*Patient self-administered* description of symptoms and complications and their duration, generic health statusVinik et al. ([@CR406])NSSNeuropathy Symptom ScoreTo detect and grade the severity of *diabetic neuropathy* based on a recorded evaluation of neurological symptoms*Clinician-administered* testing of muscle weakness, sensory disturbances, and autonomic signsDyck ([@CR116])Dyck et al. ([@CR117])TNSTotal Neuropathy ScoreTo grade severity of *diabetic polyneuropathyClinician-administered* composite measure of peripheral nerve function combining the grading of symptoms, signs, nerve conduction studies and quantitative sensory testingCornblath et al. ([@CR81])TCSSToronto Clinical Scoring SystemTo examine the presence and severity of *diabetic peripheral sensorimotor polyneuropathy* as assessed via electrophysiological criteria and myelinated fiber density on sural nerve biopsy*Clinician-administered* classical neurological history (symptom scores) and examination techniques (reflex scores and sensory test scores) and designed to be simple and relevant to the clinicianBril and Perkins ([@CR50])Validity is inconsistent and not fully convincing, as different reference standards were used. Thus, validity is not always sufficient for daily clinical practice. In these tests, pDN is often not included in validation, mostly only neuropathic symptoms are assessed but not pain in particular. This table is not exhaustive. References refer to first description of the instrument and/or, if available, to validation studies in diabetic patients

The DN4 has been validated in a population of patients with painful diabetic neuropathy (pDN) (Spallone et al. [@CR363]), which was defined as "*the presence of diabetic polyneuropathy plus chronic neuropathic pain in the same area as neuropathic deficits*"; NP was assessed based on pain history and examination, which is consistent with the grading system. DN4 showed a sensitivity of 80% and a specificity of 92%. Another study compared the DN4 and the PainDETECT with the NeuPSIG definition and grading system as the reference standard; it resulted in a sensitivity and specificity for the DN4 of 88% and 93% and for the PainDETECT of only 61% and 92% (Themistocleous et al. [@CR381]).

In a recently published systematic review regarding measurement properties of different screening tools for NP it was concluded that the Neuropathic Pain Questionnaire (NPQ) (Krause and Backonja [@CR231]) and the DN4 (Bouhassira et al. [@CR45]) were the most suitable for use in daily clinical practice (Mathieson et al. [@CR263]). However, screening tools developed before 2008 (e.g., PainDETECT; Freynhagen et al. [@CR150]) were validated against an obsolete definition of NP ("dysfunction" instead of "lesion or disease"), but not against the current definition of NP as endorsed by NeuPSIG (Treede et al. [@CR390]), IASP (Jensen et al. [@CR212]) and WHO (Scholz et al. [@CR342]). DN4 and PainDETECT correlate only moderately against the grading system (Timmerman et al. [@CR383], [@CR384]; Epping et al. [@CR127]; Tampin et al. [@CR371]). This might lead to inconclusive results in prevalence studies and inaccurate clinical diagnostics and hence, improper treatment. Therefore, screening cannot replace thorough physical examination (Timmerman et al. [@CR383]).

Bedside examination for diabetic neuropathy and neuropathic pain {#Sec16}
----------------------------------------------------------------

Bedside examination (BSE) in patients with DM is essential when suspecting diabetic polyneuropathy (dPNP) and/or pDN. Most guidelines advise yearly screening for dPNP (in T1DM starting 5 years after diagnosis, in T2DM starting immediately after diagnosis; Pop-Busui et al. [@CR312]; German National Disease Management Guideline for Diabetic Neuropathy). A thorough clinical examination, including inspection of the feet, evaluation of sensory loss, arterial pulses, skin state, pain assessment, and BSE as described below is an advisable basis. For the vast majority of patients, the diagnosis of dPNP is based on history and examination, without further necessary testing.

A typical BSE test in patients suspected for dPNP is the 128 Hz tuning fork (placed at the dorsum of the interphalangeal joint of the hallux) to examine vibration perception. It is a valid and reliable tool for screening purposes, manageable in daily clinical practice (Meijer et al. [@CR273]). Additionally, testing by monofilaments is easily applicable and has a reliable outcome. Two studies (Olaleye et al. [@CR298]; Perkins et al. [@CR306]) found the following BSE tests useful to differentiate between DM patients with and without neuropathy: The Semmes--Weinstein 10 g monofilament examination (SWME), the superficial pain sensation (via a sterile neurotip) and vibration (on--off method). Nerve Conduction Studies (NCS), often a reference standard versus screening instruments, were also suggested to be included in annual screening for dPNP (Perkins et al. [@CR306]). However, there is some evidence that one test alone is not sufficient (Brown et al. [@CR53]) and that NCS may be replaced by QST profiling (Kopf et al. [@CR228]).

BSE for pDN and NP, in general, should include a pain drawing by the patient (Hansson [@CR182]; Margolis et al. [@CR259]) and mapping of regions of sensory disturbances using at least one thermal and one mechanical test stimulus (Timmerman et al. [@CR385]; La Cesa et al. [@CR234]; Haanpaa et al. [@CR179]; Bouhassira and Attal [@CR43]; Cruccu et al. [@CR90]; Haanpaa et al. [@CR500]). According to the grading system, sensory changes should be documented within the painful region for grading of "probable NP". For a review including a well-designed table giving an overview of negative and positive symptoms of NP, see Gierthmuhlen and Baron ([@CR161]).

Confirmatory tests {#Sec17}
------------------

There are two types of confirmatory tests in the assessment of patients with NP: (a) tests that confirm the sensory changes and (b) tests that confirm the specific underlying lesion or disease of the somatosensory nervous system explaining the symptoms of the patient (Brown et al. [@CR53]; Finnerup et al. [@CR143]; Olaleye et al. [@CR298]; Perkins et al. [@CR306]).

A number of confirmatory tests to investigate somatosensory pathway function are available (Table [6](#Tab6){ref-type="table"} including a column with remarks on the application in dPNP). They can be divided into structural tests (nerve biopsy, punch skin biopsy, corneal confocal microscopy) and functional tests (quantitative sensory testing, neurophysiological techniques). These tests are used mostly in research settings or in the diagnostic workup of patients with an atypical clinical presentation (Feldman et al. [@CR135]; Tesfaye et al. [@CR378]).Table 6Confirmatory tests for lesion or disease of somatosensory system in patients with suspected neuropathic painNameObjective(s) of testDescriptionRemarks on dPNPReferencesBasic neurological examinationMapping of sensory changesInspection of feet, evaluation of clinical signs (e.g., sensory loss, allodynia, hyperalgesia), pulse state, skin state, general state of patient, reflexes etcRecommended in all guidelines.Essential for grading of NP in all patients.Holiner et al. ([@CR194])German National Disease Management Guideline for Diabetic NeuropathyPop-Busui et al. ([@CR312])Cruccu et al. ([@CR90])Quantitative sensory testing (QST)Quantification of sensory changes in a few defined areasMechanical and thermal detection and pain thresholds to assess small (C and Aδ) and large (Aβ) sensory nerve fibersQST is proven to be reliable and reproducible, and sensitive to change in NP, also in diabetic patients.Treede ([@CR389])Rolke et al. ([@CR327])Cheliout-Heraut et al. ([@CR69])Weintrob et al. ([@CR422])Hsieh ([@CR195])Backonja et al. ([@CR22])Jensen et al. ([@CR210])NerveCheckA portable QST deviceVibration and thermal testing for functional testing of large and small nerve fibersValidated against neuropathy disability score, nerve conduction studies, intraepidermal and corneal nerve fiber density.Ponirakis et al. ([@CR310])Ankle reflexesAssess muscle spindle afferents and Aα motoneuronsTendon tap by reflex hammer; assesses only large fiber functionsLoss of ankle reflexes occurs early in dPNP. Part of recommended clinical examination.Tesfaye et al. ([@CR378])Pop-Busui et al. ([@CR312])Nerve conduction studies (NCS)Estimating severity of diabetic neuropathy by testing motor (Aα) and large sensory (Aβ) nerve fibersUsually NCs of sural nerve; objective and quantitative measureChanges in amplitude of motor nerve fibers typically follow changes in amplitude of sensory nerve fibers. If NCS is normal, validated measures of small fiber neuropathy are needed.Tesfaye et al. ([@CR378])Dyck et al. ([@CR119])Dyck et al. ([@CR120])Dyck et al. ([@CR121])Apfel et al. ([@CR15])Laser-evoked potentials (LEPs)Testing small fiber function (Aδ and C): thermo-nociceptorsLaser heat pulses on hairy skin; easiest and most reliable technique for objective assessment of nociceptive fibersValidated for detection of small fiber neuropathy against skin punch biopsy.Diagnostic accuracy in diabetic small fiber neuropathy is established.Di Stefano et al. [@CR106])Cruccu et al. [@CR89])Cold evoked potentialsSmall fiber function: thermoreceptorsObjective test for thermoreception by contact stimulatorNote: validity and role in routine diagnostic are not yet established!De Keyser et al. ([@CR96])Leone et al. ([@CR240])Farooqi et al. ([@CR131])Axon reflex flare responseEfferent function of small nociceptive nerve fibersStimulation of peptidergic C-fibers by iontophoresis or heat, assessment of vasodilation by laser Doppler imagingReduced in subjects with impaired glucose tolerance and type 2 diabetic patients with and without neuropathy.Caselli et al. ([@CR63])Krishnan and Rayman ([@CR232])NeuropadEvaluate cholinergic small sympathetic nerve fiber functionA simple visual indicator test based on sweating and on color changeTest for autonomic neuropathy.Ponirakis et al. ([@CR309])Intraepidermal nerve fiber density (IENF)Gold standard for the structural diagnosis of small­fiber neuropathy (skin punch biopsy)Acquired by skin punch biopsy or blister technique at ankleInvasive, rarely used in routine diagnostic, only advised when NCS and QST are normal. IENF density correlates inversely with both cold and heat detection thresholds.Vlcková-Moravcová et al. ([@CR409])Nebuchennykh et al. ([@CR290])Shun et al. ([@CR355])Andersson et al. ([@CR13])Devigili et al. ([@CR103])Sorensen et al. ([@CR361])Alam et al. ([@CR501])Corneal confocal microscopyStructural diagnosis of small fiber neuropathyAutofluorescence of corneal nerve fibers; corneal anesthesia requiredCorrelates with IENF loss and the severity of dPNP, was more prominent in patients with pDN.Quattrini et al. ([@CR316])Mehra et al. ([@CR269])Alam et al. ([@CR501])Nerve biopsyStructural diagnosis of large fiber neuropathiesUsually biopsy of the sural nerveInvasive and highly specialized procedure requiring electron-microscopy.Not recommended for routine use.Malik et al. [@CR255])Quattrini et al. ([@CR316])Confirmatory tests have different scopes (sensory loss, surrogate nerve damage, morphology of peripheral nerve endings). Pain is per definition a subjective experience (IASP) and thus does not have a confirmatory test itself (Davis et al. [@CR94]). This table is not exhaustive

For all confirmatory tests, reference values have to be adjusted for test site, age, sex, and population. For quantitative sensory testing (QST), multi-center reference data are available for different body regions in both sexes and a broad age range (Magerl et al. [@CR252]; Pfau et al. [@CR307]; Vollert et al. [@CR411]). These reference data allow a transformation of a patient's data into Z-scores with a standard Gaussian distribution (zero mean and unity variance), provided the examiner has calibrated herself or himself for about 20 healthy subjects (Vollert et al. [@CR411]). There are also some reference data available for non-Caucasian populations (Gonzalez-Duarte et al. [@CR167]; Ezenwa et al. [@CR130]). For NCS, each laboratory is usually required to generate its own reference data. Published reference data can only be used for a broad orientation since the techniques are not standardized well enough, e.g., a normative database from a mainly Western population (USA) was found not to be suitable for a Japanese population (Hirayasu et al. [@CR191]).

Importantly, note that also "objective" instruments such as skin biopsies do not necessarily relate to the pain complaint of the patient. Although assessment of intraepidermal nerve fiber density (IENFD) through skin biopsy is validated for diagnostics of small fiber neuropathies, including dPNP (Lauria et al. [@CR239]; Tesfaye et al. [@CR378]), the correlation between IENFD and severity of NP in dPNP is still debated. A flooring effect of IENFD has been suggested (Cheng et al. [@CR72]; Shun et al. [@CR355]; Sorensen et al. [@CR361]; Themistocleous et al. [@CR381]; Truini et al. [@CR393]).

Finally, not every neuropathy in patients suffering from DM is a diabetic neuropathy. Dependent on clinical presentation, laboratory testing is advised to exclude differential diagnosis, such as thyroid disease, autoimmune disorders, infections (e.g., HIV), vitamin deficiencies (e.g., vitamin B12) or intoxications (e.g., alcohol). Thus, diabetic neuropathy is a diagnosis of exclusion (England et al. [@CR126]; Pop-Busi et al. [@CR312]; Ziegler et al. [@CR449]).

Pathophysiology of diabetic neuropathy {#Sec18}
======================================

General aspects {#Sec19}
---------------

Diabetes mellitus (DM) is a common disorder marked by persistent hyperglycemia and other metabolic disturbances, such as dyslipidemia. Increased glucose levels affect primarily cells that have a limited capacity to regulate their glucose intake, including vascular cells, Schwann cells, and neurons of the peripheral and central nervous systems. Consequently, hyperglycemia leads to largely intractable complications such as retinopathy, nephropathy, hypertension, and neuropathy. However, not all patients with DM develop diabetic polyneuropathy (dPNP). In prospective studies with diabetic patients, environmental risk factors for the development of neuropathy in type 1 (T1DM) (Tesfaye et al. [@CR377]) and type 2 diabetes (T2DM) (Andersen et al. [@CR14]) were investigated: They include poor glycemic control (for T2DM Pop-Busui et al. [@CR311]) and common cardiovascular risk factors (e.g., hypertension, raised triglycerides, obesity, smoking). Genetic risk factors might also contribute to the pathogenesis of dPNP (reviewed in Prabodha et al. [@CR313]).

Peripheral diabetic neuropathy can present as several different patterns (see "[Clinical presentation of painful diabetic neuropathy](#Sec26){ref-type="sec"}"). Damage primarily occurs in sensory neurons, resulting in positive symptoms (e.g., pain, paresthesias) and negative symptoms, such as sensory loss (e.g., numbness). The most common pattern is the distal symmetric polyneuropathy, which clinically presents as a neuropathy not only predominantly of the feet, but also of the hands, with a distal-to-proximal gradient of severity (Callaghan et al. [@CR56]).

Pathogenesis of diabetic polyneuropathy {#Sec20}
---------------------------------------

Evidence of the pathogenesis of dPNP has accumulated over the past decades, delineating alterations in neurons, glia, immune cells and vascular cells in the progress of DM leading to loss of peripheral nerve function (Fig. [2](#Fig2){ref-type="fig"}; reviewed in Feldman et al. [@CR135]; Feldman et al. [@CR134]; Schreiber et al. [@CR344]; Sloan et al. [@CR358]; Yagihashi et al. [@CR436]). Many metabolic and vascular maladaptive responses have been described. Recently, the research focus turned to uncover interactions with Schwann cells and other non-neuronal cells, endoplasmatic reticulum stress, neurodegeneration, and mitochondrial dysfunction.Fig. 2Selection of structural and functional alterations in diabetic neuropathy. *AGE* advanced glycation end products, *ROS* reactive oxygen species

Most data were obtained in preclinical studies investigating animal models of T1DM (streptozotocin) and less so of T2DM using diet or genetically induced DM (reviewed in O\'Brien et al. [@CR296]; Sullivan et al. [@CR369]). These animals develop primarily distal axon loss, systemic injury of the peripheral nervous system and altered interactions with Schwann cells, which is recognized as a model for dPNP.

Evidence supports that the entire primary sensory neuron is targeted by diabetes. However, it remains elusive whether damage first targets peripheral axons and their associated Schwann cells or the neuron perikarya that reside in the dorsal root ganglia (DRG) where they are not protected by a blood--nerve barrier. Although dPNP is not considered primarily a demyelinating neuropathy, Schwann cells are targeted by chronic hyperglycemia and more severe cases of dPNP in patients include features of demyelination (Feldman et al. [@CR134]; Kobayashi and Zochodne [@CR227]).

Hyperglycemia and dyslipidemia are key players in the development of dPNP. This substrate overload leads to the accumulation of toxic metabolites and mitochondrial dysfunction, promoting metabolic, and oxidative stress and axonal degeneration (Fernyhough [@CR137]; Fernyhough and McGavock [@CR138]). Glucose excess leads to polyol and hexosamine pathway hyperactivity, resulting in both increased reactive oxygen species (ROS) and inflammation, adding to mitochondrial injury (Feldman et al. [@CR134]). Moreover, glycation of numerous structural and functional proteins leads to the production of advanced glycation end-products (AGEs). AGEs result in altered or loss of protein function and interact with AGE-specific receptor modifying gene expression, intracellular signaling, and promoting the release of pro-inflammatory molecules and free radicals (Singh et al. [@CR357]). More recently, researchers have focused on dyslipidemia in mediating additional inflammation and ROS accumulation with continued and progressive nerve injury.

Microvascular alterations induce impaired nerve perfusion provoking hypoxia and loss of nerve function (Tesfaye et al. [@CR376]). Increases in endoneurial capillary density are present in diabetic patients, suggesting that capillary density may respond to diabetes-induced nerve ischemia (Thrainsdottir et al. [@CR382]). Furthermore, altered bioavailability of different mediators including insulin growth factors, vascular endothelial growth factor (Schratzberger et al. [@CR343]) as well as gasotransmitters (e.g., NO, CO, H~2~S) (van den Born et al. [@CR402]) contributes to both vascular disease and neuropathy in diabetes.

Although neurotrophic effects of insulin on sensory nerves have been shown (Frazier et al. [@CR147]), correcting hyperglycemia with insulin has little effect on dPNP in patients with T2DM. By contrast, in T1DM patients with dPNP, normoglycemia through insulin treatment provides a substantial therapeutic benefit (Grote and Wright [@CR177]). Inflammatory processes may be relevant, especially in the onset of dPNP and in developing pDN (Herder et al. [@CR189]; Magrinelli et al. [@CR254]).

Painful vs. painless diabetic neuropathy {#Sec21}
----------------------------------------

Only about 20--50% of patients with DM and about 60% of dPNP patients develop NP. The reason why some patients experience NP while others do not is not fully understood. However, there has been growing evidence on risk factors (demographic, metabolic, sensory, genetic) for developing NP in dPNP (Shillo et al. [@CR354]). Large, well-characterized, cross-sectional cohort studies have given valid insights into risk factors (Fig. [3](#Fig3){ref-type="fig"}) and somatosensory profiles of pDN. However, longitudinal studies are lacking.Fig. 3Pathophysiology of painless and painful diabetic neuropathy: diabetes mellitus leads to several pathological changes in neuronal, immune and vascular cells that can lead to structural and functional alterations of the nervous system that can result in diabetic neuropathy (see Fig. [2](#Fig2){ref-type="fig"}). Several factors contribute to the development of neuropathic pain in diabetic neuropathy. *AGE* advanced glycation end products, *HIF-1α* hypoxia-induced factor 1α, *PKC* protein kinase C, *TRPA1* transient receptor potential ankyrin 1, *VGSC* voltage-gated sodium channel, *vWF* von Willebrand factor

NP in dPNP seems to be associated with the female gender (Truini et al. [@CR394]), increasing age (Van Acker et al. [@CR401]), and ethnicity (Hebert et al. [@CR187]). Metabolic issues including obesity (Ziegler et al. [@CR450]), elevated HbA1c (Themistocleous et al. [@CR381]), high alcohol intake, duration, and type of DM, might increase the risk of developing NP. The sensory phenotype and neuropathy severity are also associated with pDN (Raputova et al. [@CR322]). Genetic variants (Blesneac et al. [@CR38]; Prabodha et al. [@CR313]) and genetic variability are likely to interact with the environment to determine the risk of developing pDN.

### Peripheral mechanisms of painful diabetic neuropathy {#Sec22}

For long time, it has been known that microvascular alterations, such as structural and functional abnormalities of the vasa nervorum (Cameron et al. [@CR59]) and altered regulation of peripheral blood flow (Archer et al. [@CR16]) are associated with pDN. More recently, dysregulation of the local blood flow in the skin, involving hypoxia-induced factor 1-alpha (Quattrini et al. [@CR317]) and von Willebrand factor (vWF) (Shillo et al. [@CR353]), has been found to contribute to NP. NP-related behavior has been found to be related to numerous metabolic pathways. There is limited evidence to support glycemic control or lifestyle modifications in reducing NP (Pop-Busui et al. [@CR312]). Preclinical studies indicate that vitamin D plays a critical role in nerve function in health and possibly in NP syndromes (Fukuoka et al. [@CR152]). Vitamin D levels have been found to be significantly lower in patients with painful compared to painless diabetic neuropathy (Shillo et al. [@CR354]).

There might be a special role for methylglyoxal (MGO) in pDN. In rodent models of pDN, MGO induced signs of hypersensitivity via activation of the sodium channel Nav1.8 and transient receptor potential channel ankyrin 1 (TRPA1) (Bierhaus et al. [@CR36]; Huang et al. [@CR196]). MGO induces pain, axon-reflex-erythema, and long-lasting hyperalgesia via the activation of C-nociceptors in healthy humans. TRPA1 is crucially involved in MGO-induced pain sensation and heat hyperalgesia (Dull et al. [@CR111]).

### Central mechanisms of painful diabetic neuropathy {#Sec23}

Studies of the CNS demonstrate clear differences in painful compared to painless diabetic neuropathy. Spinal, somatomotor, limbic, thalamic, ascending, and descending modulatory systems demonstrate structural and functional alterations (Tesfaye et al. [@CR379]). Changes in higher brain centers are also described in patients with pDN: cortical atrophy within the somatomotor cortex and insula (Selvarajah et al. [@CR349]; Shillo et al. [@CR352]), abnormal cortical interactions within the somatomotor network (Selvarajah et al. [@CR348]), and increased cerebral blood flow in the anterior cingulate cortex (Watanabe et al. [@CR419]). It is still unknown whether the described CNS changes are only a response to afferent input of the peripheral nervous system or a primary mechanism responsible for the maintenance of pDN.

Clinical presentation of painful diabetic neuropathy {#Sec24}
====================================================

Painful diabetic neuropathy (pDN) is defined as "*pain arising as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes*" (Tesfaye et al. [@CR378])*.* According to this guideline, pDN is diagnosed if pain lasted ≥ 3 months has a history of confirmed dPNP and an association with abnormal sensory signs of small fiber and large fiber neuropathy in a neuro-anatomically plausible distal and symmetrical distribution. The stepwise procedure (Table [4](#Tab4){ref-type="table"}) consisting of a history of disease, examination, and confirmatory testing should also be pursued in patients with a suspected pDN.

Distribution of both pain and sensory changes should be mapped (Cruccu et al. [@CR90]; Hansson [@CR182]; Margolis et al. [@CR259]). The sensory changes are usually in a distal, symmetrical distribution (stocking or glove like): decreased sense of vibration, impairment of proprioception, reduced or even absent reflex activity in the Achilles tendon and diminished muscle strength or atrophy of the foot muscles, which might lead to pes cavus or hammertoes (Dyck et al. [@CR118]; England et al. [@CR126]; Martin [@CR261]; Peltier et al. [@CR305]). However, in pDN, symmetrical, distal pain or numbness may also be the only indicative factors (Tesfaye et al. [@CR378]).

Paradoxically, lesions or diseases affecting the somatosensory nervous system do not only lead to a loss of function, but also to overexcitability and increased sensitivity to painful stimuli (hyperalgesia), pain sensations to normally non-painful stimuli (allodynia) and spontaneous pain. pDN patients often describe a prickling, burning, deep aching, sharp, stabbing, and/or electric pain. Signs of sensory gain were traditionally thought to be rare in pDN, but recent studies using QST demonstrated a high prevalence of mechanical hyperalgesia in pDN (Themistocleus et al. [@CR381]; Vollert et al. [@CR412]; Kopf et al. [@CR228]). Preserved small fiber function combined with thermal hyperalgesia ("*irritable nociceptor*" phenotype) is much less frequent in pDN (\< 10%) than in postherpetic neuralgia, where it was originally described (Fields et al. [@CR139]; Baron et al. [@CR29]; Edwards et al. [@CR123]; von Hehn et al. [@CR413]). In most pDN patients, sensory loss of small and large fibers is pronounced ("*deafferentiation*" phenotype), while deep tissue mechanical pain (assessed by pressure pain threshold) is relatively intact (Themistocleous et al. [@CR381]; Baron et al. [@CR29]; Vollert et al. [@CR412]).

Small fiber neuropathy in DM may also lead to autonomic nervous system deficits in addition to cutaneous sensory loss and pain. Clinicians need to keep an eye on the usually slower developing autonomic diabetic neuropathy, which affects the cardiovascular, gastrointestinal or genitourinary system (Edwards et al. [@CR122]) and is important for prognosis. In some cases, diabetic neuropathy with neuropathic symptoms may manifest even before DM has been diagnosed (Tesfaye et al. [@CR378]), making diagnostics difficult.

Implications for management {#Sec25}
===========================

Management of diabetic neuropathy {#Sec26}
---------------------------------

Currently, there are three main elements in the management of diabetic polyneuropathy (dPNP): glycemic control, foot care, and symptomatic treatment, and predominantly pain therapy.

### Glycemic control {#Sec27}

While diabetes is defined by increased glucose levels and tight glycemic control has a high value in its treatment, it is currently recommended to individualize glycemic control in patients with T2DM considering the benefit/risk ratio (Rodriguez-Gutierrez et al. [@CR326]; Qaseem et al. [@CR315]). Hyperglycemia is not the prime driving cause of all complications (Tesfaye et al. [@CR378]). Otherwise, diabetic complications including dPNP could be easily prevented and symptoms should be reduced by efficient glycemic control (Stolar [@CR366]). While there is convincing evidence that enhanced glucose control significantly reduces or delays the incidence of developing clinical neuropathy in T1DM (Fullerton et al. [@CR153]; Albers et al. [@CR5]), the data in the more frequent T2DM remain elusive (Pantalone et al. [@CR299]; Callaghan et al. [@CR57]; Ismail-Beigi et al. [@CR204]; Calles-Escandon et al. [@CR58]; UKPSD Study Group [@CR399]).

Comparing the effect of glycemic control, Callaghan and colleagues proposed that mechanisms of dPNP in T1DM and T2DM are fundamentally different, which should be considered in its treatment (Callaghan et al. [@CR57]), still, a recent cohort study emphasizes that early, intensive glycemic control may be necessary to avoid diabetic complications and mortality (Laiteerapong et al. [@CR237]). Interestingly, aggressive glucose control not only significantly increases the risk of severe hypoglycemic episodes (Callaghan et al. [@CR57]), but can also result in treatment-induced neuropathy if glycemic control is achieved too quickly and to too low glucose levels (Gibbons [@CR158], [@CR159]; Hwang and Davies [@CR198]). It is suggested that neurons take up much more glucose than other cell types and, therefore, are more vulnerable to hypoglycemia (Low and Singer [@CR247]; Gibbons and Freeman [@CR160]).

### Foot care {#Sec28}

dPNP is the primary risk factor for the development of foot ulcers, increasing devastating outcomes of ulcerations that risk amputations (Ahmad [@CR3]; Boulton [@CR49]). Management includes patient education, plantar pressure relief with orthoses and appropriate footwear, regular skin, nail and ulcer care (e.g., paring of calluses, debridement of infected or nonviable tissue) (Pinzur et al. [@CR308]; Kavitha et al. [@CR219]).

Management of neuropathic pain and painful diabetic neuropathy {#Sec29}
--------------------------------------------------------------

Management of neuropathic pain (NP) in general and painful diabetic neuropathy (pDN) in particular is a challenge. A number of clinical practice guidelines, e.g., by the International Association for the Study of Pain (IASP) (Finnerup et al. [@CR142]; Dworkin et al. [@CR115]; Haanpaa et al. [@CR179]), the European Federation of Neurological Societies (EFNS) (Attal et al. [@CR18]; Cruccu et al. [@CR90]), the National Institute for Health and Care Excellence of the UK (NICE; Tan et al. [@CR372]), the Canadian Pain Society (CPS; Moulin et al. [@CR286]), the German Society for Neurology (DGN) and German National Disease Management Guideline for Diabetic Neuropathy have been published to facilitate assessment and management of NP also in patients with DM. Management rests on three pillars: management of diabetes, management of diabetic neuropathy, and symptomatic treatment of NP.

Between these guidelines, there is broad agreement regarding pharmacological management of NP (Finnerup et al. [@CR142]; Deng et al. [@CR99]; Cruccu and Truini [@CR88]).All guidelines strongly recommend three drug classes for first-line therapy of nearly all described syndromes: tricyclic antidepressants (particularly amitriptyline), serotonin--norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine) and calcium channel alpha-2-delta ligands gabapentin and pregabalin.Second-line recommendations by most guidelines (NICE: only rescue therapy because of higher withdrawal due to adverse events and weak study evidence) is tramadol (weak opioid + SNRI).Third- and fourth-line treatments commonly include strong opioids, anti-convulsants (other than gabapentinoids), and cannabinoids.

Depending on the syndrome, there are some specific recommendations, such as carbamazepine for trigeminal neuralgia or topical agents such as dermal patches releasing lidocaine or capsaicin and subcutaneous injection of botulinum toxin for localized NP (Mick et al. [@CR275]; Allegri et al. [@CR8]). HIV-related NP is more refractory to pharmacotherapy than other types of NP (Finnerup et al. [@CR142]). Opioids should be reserved for patients not responding to therapeutic alternatives because their long-term use carries a high risk of adverse effects and they are effective in the long run only in a small number of patients (for those patients, they may be a valuable element of their multimodal pain management). Nonsteroidal anti-inflammatory drugs have no proven efficacy against pain of purely neuropathic origin; however, they can be useful in mixed pain syndromes (Vo et al. [@CR410]).

The latest NeuPSIG guidelines (IASP) are based on a large meta-analysis, including unpublished trials (Attal and Bouhassira [@CR503]; Finnerup et al. [@CR142]; Cruccu and Truini [@CR88]). These guidelines do not focus on etiologies, but treat NP as a specific entity because the efficacy of systemic treatments seems not to be affected by etiology. This unifying concept has been adopted by EMA for licensing of medications in Europe and is represented in Table [7](#Tab7){ref-type="table"}. The FDA, however, still requests two independent studies per indication for licensing in the U.S.A. Depending on the country, some drugs have not been tested or approved for NP of certain underlying diseases; this needs to be verified locally before following any of these guidelines (Finnerup et al. [@CR142]; Attal et al. [@CR18]; Cruccu et al. [@CR90]; Haanpaa et al. [@CR179]; Dworkin [@CR114]).Table 7Pharmacotherapy for neuropathic painDrug classMechanism of actionRepresentativesLicense^a^Strength of recommendation^b^NNT^c^Additional benefits^d^References*Anticonvulsants*Calcium channel alpha-2-delta ligand, reduces the synaptic release of several neurotransmitters, channel modulatorGabapentin*General NP*Strong; 1st line*6.3 (5.0--8.3)*3.3--7.2No clinically significant drug interactionsadditionally for pregabalin:improvement of anxiety and sleepGoodman and Brett ([@CR168])Dworkin et al. ([@CR114])Moore et al. ([@CR284])Wiffen et al. ([@CR423])ER/enacarbil*General NP*Strong; 1st line*8.3 (6.2--13.0)*Pregabalin*General NP*FDA: pDNStrong; 1st line*7.7 (6.5--9.4)*3.3--8.3Freynhagen et al. ([@CR149])Roth et al. ([@CR328])Goodman and Brett ([@CR168])Derry et al. ([@CR102])Sodium channelCarbamazepine*TN*InconclusiveNot reportedCollins et al. ([@CR79])blockerOxcarbazepineZhou et al. ([@CR444])*Antidepressants*TCANorepinephrine and serotonin reuptake inhibitor, block of voltage-gated sodium channels, anticholinergic effectsAmitriptylineNortryptilin DesipramineImipramine*General NP*Strong; 1st line*3.6 (3.0--4.4)*2.1--4.2Improvement of depression and sleep disturbancesSaarto et al. ([@CR329])Attal et al. ([@CR18])Dworkin et al. ([@CR114])Finnerup et al. ([@CR140])Moore et al. ([@CR285])Hearn et al. ([@CR185])Hearn et al. ([@CR186])SNRINorepinephrine and serotonin reuptake inhibitorVenlafaxineStrong; 1st line*6.4 (5.2--8.4)*5.2--8.4Improvement of depression and general anxiety (for both listed drugs)Zin et al. ([@CR452])Trouvin et al. ([@CR392])Gallagher et al. ([@CR154])Aiyer et al. ([@CR4])Norepinephrine and serotonin reuptake inhibitorDuloxetine*pDN*FDA: pDNStrong; 1st line*6.4 (5.2--8.4)*3.8--11.0Snyder et al. ([@CR360])Lunn et al. ([@CR249])Attal et al. ([@CR18])Dworkin et al. ([@CR114])Finnerup et al. ([@CR140])Saarto et al. ([@CR329])*Local therapeutics*Local anestheticsSodium channel blockerLidocaine (patch, 5%)*Peripheral NP*Weak; 2nd line(1st line option in elderly and frail patients)Not reportedNo systemic side-effectsWolff et al. ([@CR425])Zur et al. ([@CR454])Peltier et al. ([@CR305])Yang et al. ([@CR437])Local capsaicinTRPV1 agonist reversible defunctionalization of nociceptor fibersCapsaicin (patch, 8%)*Peripheral NP*Weak; 2nd line*10.6 (7.4--18.8)*No systemic side effectsYang et al. ([@CR437])Derry et al. ([@CR101])Vinik et al. ([@CR408])Botulinum toxin type AAcetylcholine release inhibitor, neuromuscular blocking, potentially also mechano-transduction and central effects of NPBOTOXWeak, 3rd line*1.9 (1.5--2.4)*Potential effect on neurogenic inflammationPark and Park ([@CR301])Safarpour and Jabbari ([@CR331])Yuan et al. ([@CR439])*Opioids*µ-Receptor agonist, norepinephrine and serotonin reuptake inhibitorTramadolWeak, 2nd line*4.7 (3.6--6.7)*3.1--6.4Also against inflammatory pain; rapid onsetDuehmke et al. ([@CR112])Zin et al. ([@CR452])µ-Receptor antagonist, noradrenaline reuptake inhibitorTapentadolFDA: pDNnot reportedRapid onsetSchwartz et al. ([@CR346])Freo et al. ([@CR148])Strong opioidsµ-Receptor agonistκ-Receptor antagonistMorphineWeak, 3rd line*4.3 (3.4--5.8)*Rapid onsetCooper et al. ([@CR80])µ-Receptor agonistOxycodoneWeak, 3rd line*4.3 (3.4--5.8*)Rapid onsetGimbel et al. ([@CR164])Watson et al. ([@CR421])*Cannabinoids*CB1 receptor agonistsNabiximol*NP*Weak againstNot reportedKarst et al. ([@CR218])Meng et al. ([@CR274])Wallace et al. ([@CR415])*NP* neuropathic pain, *pDN* painful diabetic neuropathy, *TN* trigeminal neuralgia^a^License according to *EMA*, if licensed by the FDA for the indication pDN = FDA: pDN^b^NeuPSIG GRADE recommendations for NP in general (Finnerup et al. [@CR142])^c^For NP in general: *Finnerup et al.*([@CR142]) (95% CI in brackets), for the indication pDN if reported: Pop-Busui et al. ([@CR312])^d^Additional benefits adapted from Baron et al. ([@CR27])

Although NP is no longer considered chronic intractable pain, meta-analyses and systematic reviews on NP indicate that only a minority of patients have an adequate response to drug therapy (Baron et al. [@CR27]; Tan et al. [@CR372]; Finnerup et al. [@CR142]; Bril et al. [@CR52]; Moulin et al. [@CR286]; Scholz et al. [@CR342]). Only one-third of pDN patients experience satisfying pain relief; the same is found for other patients with NP (Jensen et al. [@CR211]). Mostly, complete freedom of pain cannot be achieved; however, improvement of life quality, sleep, social activities and ability to work is possible, which should be addressed in patient education (Baron and Binder [@CR37]; Finnerup et al. [@CR142]). In clinical practice, combination pharmacotherapy is often applied, although the evidence for guiding such combinations is weak (Gilron and Jensen [@CR163]; Chaparro et al. [@CR67]). In individual patients, second- or third-line medications may be more effective than medications coming out as first-line treatment from clinical trials. Thus, the management of patients with pDN or NP has to be on an individual basis. Non-pharmacological approaches and a generally multidisciplinary management of NP, including physical and psychological therapy and interventional approaches, need to be considered earlier (Finnerup et al. [@CR142]; Scholz et al. [@CR342]; Dworkin et al. [@CR115]; Torrance et al. [@CR387]).

Outlook: individualized therapy of painful diabetic neuropathy {#Sec30}
--------------------------------------------------------------

Like in other fields of medicine, sex differences and genotype are thought to play a role in predicting treatment responses in pDN and NP (Zorina-Lichtenwalter er al [@CR453]; Belfer and Dai [@CR33], van Hecke et al. [@CR403]). Genetic factors may increase the risk of developing NP and predict the response to drugs with different mechanisms of actions (Dworkin et al. [@CR113]; Spallone [@CR364]). So far, these factors do not play a role in designing the individualized treatment plans for patients with pDN or NP in general.

Another approach to identify possible responder populations is stratification according to the sensory phenotype of the patients, e.g., according to their QST profile or conditioned pain modulation (CPM) (Attal et al. [@CR19]; Baron et al. [@CR28]; Treede [@CR391]). Recent multicenter clustering studies using QST parameters in patients with NP of different origins identified three subgroups (sensory loss, thermal hyperalgesia, and mechanical hyperalgesia; Vollert et al. [@CR412]). Stratifying patients according to their underlying distinct mechanisms may help to decrease NNTs (Baron et al. [@CR29]), e.g., NNT of oxcarbazepine differed between 3.9 in the irritable and 13 in the non-irritable nociceptor phenotype (Demant et al. [@CR98]). Clonidine significantly reduced foot pain associated with pDN in a subgroup of patients with a preserved nociceptor function screened using 0.1% capsaicin (Campbell et al. [@CR62]). Patients with pDN with a less efficient CPM, reflecting a malfunctioning pain modulation by the monoaminergic descending pathways, showed a better efficacy of duloxetine treatment (Yarnitsky et al. [@CR438]).

Stratification according to patient-reported questionnaires such as NPSI or painDETECT seems promising (Forstenpointner et al. [@CR146]; Bouhassira et al. [@CR48]). Studies analyzing patterns of sensory symptoms found that classification based on the symptom clusters was more appropriate than based on etiology (Attal et al. [@CR17]; Baron et al. [@CR29]). In spite of the recent progress towards an individualized mechanism-based pain therapy based on the sensory phenotype, which may reflect differences in underlying mechanisms, more research is needed before personalized medicine can reach pDN patients.

Research agenda {#Sec31}
===============

Although considerable research has been devoted to uncovering mechanisms of painful diabetic neuropathy (pDN) and neuropathic pain (NP) in general, treatment options to eliminate the root causes are still lacking. The research agenda for mechanism-based treatment of NP proposed in 1990 is still valid (Max [@CR264]): "*The identification of more effective, less toxic treatments that can be individualized to patients with particular underlying mechanisms requires several coordinated research approaches:*development of drugs that correct particular pathophysiological mechanisms in animal models of neuropathic pain;delineation of classifications of neuropathic pain patients that correspond to the underlying pathophysiology of their pain;clinical trials designed to cull out specific subsets of patients responding to a particular treatment."

Pharmacological targets {#Sec32}
-----------------------

Current therapeutic strategies for NP, in general, aim to reduce the excitability of neurons in the peripheral and central nervous system by modulating the activity of ion channels (e.g., application of lidocaine and capsaicin), by modulating synaptic transmission (e.g., gabapentinoids) or by mimicking and enhancing endogenous inhibitory mechanisms (e.g., tricyclic antidepressants, duloxetine, and opioids). However, there is still a large gap between theoretically effective target mechanisms and actual efficacy in clinical studies.

After the discovery of complete insensitivity to pain in patients with null mutations in the sodium channel Nav1.7 (Cox et al. [@CR85]), both academia and industry have worked intensively on specific Nav1.7 inhibitors. Until now, there has been no successful clinical trial on pain relief due to targeting selectively Nav1.7, which demonstrates the difficulties of the translation of the even most compelling targets into therapeutics. Lacosamide has a certain preference for Nav1.7, but is licensed only for the treatment of epilepsy in spite of some evidence for efficacy in pDN (Rauck et al. [@CR323]; Wymer et al. [@CR433]).

Considering the role of immune cells and glia in the development of NP, there has been great interest in therapeutically targeting neuroinflammation. However, most of the broad array of compounds (reviewed in Mika [@CR278]) that successfully inactivate or disrupt glial function and attenuate pain-responsive behavior in animal models of NP are inappropriate for human application. Minocycline, a commonly used second-generation tetracycline antibiotic and non-specific blocker of microglial activation, demonstrated very promising results in the reduction of NP in preclinical studies. However, the efficacy of minocycline in clinical trials was disappointing (Martinez et al. [@CR262]; Vanelderen et al. [@CR404]; Sumitani et al. [@CR368]; Curtin et al. [@CR93]). Metformin, an oral antidiabetic used to treat T2DM, reduces microglia surrounding sensory neurons in the spinal cord and blocks neuropathic hypersensitivity in male mice, but seems to worsen the situation in females (Inyang et al. [@CR203]). Sex differences in the role of microglia in NP mechanisms (more predominant role in male rodents) have recently dampened enthusiasm for this treatment target (North et al. [@CR293]; Sorge et al. [@CR362]).

Targeting metabolic and inflammatory alterations in diabetic polyneuropathy (dPNP) has been promising in preclinical animal models (reviewed in Dewanjee et al. [@CR105], Edwards et al. [@CR122]). The clinical translation, however, is challenging. Currently, glycemic control and improved lifestyle remain the only disease-modifying therapies for dPNP. Benfotiamine, targeting the hexosamine pathway (Sanchez-Ramirez et al. [@CR335]; Stracke et al. [@CR367]), actovegin, improving tissue glucose and oxygen uptake (Ziegler et al. [@CR448]) and the antioxidant alpha-lipoic acid (Papanas and Ziegler [@CR300]; Ziegler et al. [@CR446]; Ametov et al. [@CR10]) are some of the very few strategies that lead to pain reduction in pDN patients in clinical trials among pathogenesis-oriented treatment of dPNP. However, none of them is currently approved and most of the strategies that succeeded in preclinical studies were either not tested in humans or failed in clinical trials (Dewanjee et al. [@CR105]; Chalk et al. [@CR66]; Grewal et al. [@CR175]). Failure has been attributed to trial design and the inability to reach therapeutic plasma levels without toxic side effects. However, there is still extensive preclinical research on further mechanisms and new targets ongoing.

For the management of NP in general, prospective targets include several intracellular signaling pathways (Khangura et al. [@CR222]). For dPNP and pDN in particular, recent strategies have also addressed modulating well-known targets with new pharmaceuticals, e.g., lacosamide, fulranumab and mirogabalin (Wymer et al. [@CR433]; Rauck et al. [@CR323]; Wang et al. [@CR417]; Vinik et al. [@CR407]).

Preclinical models {#Sec33}
------------------

One key factor for the successful clinical translation is choosing the adequate preclinical animal models of the disease and adequate outcome measures (Gregory et al. [@CR173]; St John Smith [@CR365]). The most frequently used rodent models look at the effects of partial mechanical nerve damage using reflex measures of stimulus-evoked pain; these models exhibit a similar sensory phenotype as peripheral nerve injury in humans (Gierthmuhlen et al. [@CR162]), but bear poor resemblance to the clinical appearance of most NP patients.

Models that try to resemble human pDN (Gao and Zheng [@CR155]) include high-dose streptozotocin that is toxic to pancreatic insulin-secreting β-cells and genetically modified strains are used to mimic the metabolic phenotype of T1DM. There are genetic and diet-induced animal models available to investigate NP in T2DM. However, currently, no single rodent model accurately mimics human pDN (O'Brien et al. [@CR296]).

Moreover, the difference in pain assessment is a major problem: patients with NP primarily suffer from ongoing pain that is independent of external stimuli that is hard to measure in rodents (Tappe-Theodor and Kuner [@CR375]). Current approaches assess pain-induced changes in gait (dynamic weight-bearing), housekeeping (burrowing), exploratory behavior (elevated plus maze, open field) or learned helplessness (forced swim test, tail suspension test).

Most knowledge about mechanisms of dPNP, pDN, and NP was gained in genetically homogenous male rodents, while patients vary in sex, ethnicity and genetic background, age, and duration of the underlying disease. To make future preclinical studies more predictive for the clinical situation, several design parameters should be expanded: (1) the wide variety of potential underlying lesions or diseases of NP suggests that a variety of models should be studied. (2) Multiple endpoints should be assessed including measures of both evoked and ongoing pain. (3) Comorbidities and quality of life should be assessed. (4) Animals with genetic variability should be used, e.g., outbred strains. (5) Studies should be done in male and female animals.

Clinical trial design {#Sec34}
---------------------

Another key factor for a better clinical translation of preclinical studies is an improvement in clinical trial design. Compared with fields like oncology or infectious diseases, clinical trials on treating pain conditions can be quite primitive in assuming that all pain is one and the same. In the presence of evidence for multiple distinct mechanisms of pain generation, it is necessary to shift paradigms towards more specific mechanism-based indications. Clinical practice is moving towards individualized pain management, so it is advisable for the pharmaceutical industry to move in the same direction and supply the necessary specific analgesics. The European Medicines Agency published guidelines on how to conduct trials for the development of pharmaceutics for pain therapy. This guideline encourages stratification according to the phenotype (QST profile or CPM, including assessment of stimulus-evoked pain) of the patients as a first step to identify possible responder populations for existing or future medication (Cruccu and Trunini [@CR87]; Attal et al. [@CR19]; Baron et al. [@CR28]; Baron et al [@CR29]; Treede [@CR391]). As in preclinical studies, clinical trials should include participants of both sexes, with appropriate precautions for women of childbearing age. After all, women are more frequently affected by NP than men. Finally, pain intensity as a primary endpoint should be replaced by pain severity, which is a combination of pain intensity, distress, and functional impairment (Treede et al. [@CR391]).

Conclusion {#Sec35}
==========

Treatment of NP, in general, and pDN, in particular, is challenging. Treatment of the underlying lesion or disease has been stated as a goal of NP management. This may sound manageable for dPNP via glycemic control, but clinical experience indicates that this concept holds only for T1DM, but less so for T2DM. Moreover, treating the neuropathy does not always alleviate the pain. Therefore, there is a continuing need for better analgesic medications for pDN and NP. Clinically, the field moves towards individualized pain management, which necessitates a mechanism-based pharmacotherapy of pDN. For this purpose, predictors and biomarkers need to be validated for both clinical trials and clinical practice. Several candidates have already been proposed (genetics, sex, sensory phenotype), so significant progress is expected to be made over the coming years.
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